



<b>TX(earp)</b>		<b>63512</b>	<b>349657</b>	<b>765847</b>	<b>722238</b>	<b>887795</b>	<b>1397412</b>	<b>377011</b>	<b>336849</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4900321</b>	<b>84%</b>	<b>100%</b>
<b>TX(arv)</b>		<b>155</b>	<b>925</b>	<b>2338</b>	<b>1385</b>	<b>2174</b>	<b>2967</b>	<b>1222</b>	<b>772</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>11938</b>	<b>74%</b>	<b>100%</b>
<b>TX(hrv)</b>		<b>121</b>	<b>798</b>	<b>1164</b>	<b>1047</b>	<b>1710</b>	<b>2157</b>	<b>603</b>	<b>279</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>7879</b>	<b>74%</b>	<b>100%</b>

ATO: Annual Treatment Objective TX: Number Treated earp: Eligible At Risk Population arv: At Risk Villages hrv: High Risk Villages (nodule prevalence >39% or mf prevalence>59%)

\*OEPA figures reported quarterly: hrv villages reflect prevalence at time of initiation of Mectizan therapy; Mexico uses >49% mf prevalence as hrv definition  
Number of hrv villages in Uganda is unknown